|
|
|
|
|
|
A conversation with Patrick Statham | A European consortium achieved greater T cell expansion compared to baseline conditions using real-time process monitoring and control. | |
|
|
| Facts About AAV Producer Cell Lines | Article | Cytiva | Gene therapies are revolutionizing medicine, with AAV vectors leading the way. As production evolves, stable cell lines may replace transient transfection and unlock scalable solutions. |
|
|
| Purification Of Complex mAb Modalities: Ask The Specialists | Q&A | With Jett Appel, Nicholas Bardol, and Kelly Flook, Thermo Fisher Scientific | Traditional mAb purification methods often fall short with complex modalities. Discover how experts tackle new impurities and structural complexities to enhance therapeutic antibody purification. |
|
|
|
| Tips For Designing A Single-Use Manifold For Advanced Therapies | Article | By Jay Collins and Chris Hofmann, Charter Medical | Expert single-use engineers address six common questions posed by cell and gene therapy manufacturers in the design of custom single-use manifolds for the critical handling of biological fluids. |
|
|
|
|
|
| Key Processes Of The T Cell Therapy Workflow In Chemically Defined Media | Poster | By Anastassia Tselikova, Shahram Shahabi, and Chandana Sharmah, FUJIFILM Biosciences | Delve into how chemically defined media supports robust cell expansion and function across key T cell therapy workflow steps, including a wash-free cryopreservation and thaw process for simplified scale-up. |
|
|
|
|
|
|
| Data-Driven CHO Bioprocess Optimization And Scale-Up | Application Note | Repligen – PAT | Get information on how at-line cell culture media analysis enhances mAb production by refining nutrient feed strategies, reducing toxic metabolites, and improving yields while lowering costs. |
|
|
|
|
|
|
|
|
|
|
|
|
| Advancing the Future of Cell & Gene Therapy | This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines. Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now |
|
|
| Connect With Cell & Gene: |
|
|
|